Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
19.11
-1.15 (-5.68%)
At close: May 12, 2026, 4:00 PM EDT
19.05
-0.06 (-0.31%)
Pre-market: May 13, 2026, 8:12 AM EDT
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1α, IL-1β and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Name | Position |
|---|---|
| Dr. John C. Castle Ph.D. | Chief Data & Information Officer |
| Dr. Markus Warmuth M.D. | President, CEO & Director |
| Dr. Sharon Townson Ph.D. | Chief Scientific Officer |
| Mr. Andrew Funderburk | Chief Investor Relations and Strategy Officer |
| Mr. Filip Janku M.D., Ph.D. | Chief Medical Officer |
| Mr. Magnus Walter DPHIL | Chief Technology Officer |
| Mr. Matthew Bowen | Corporate Controller & Principal Accounting Officer |
| Mr. Philip Nickson J.D., Ph.D. | Chief Business & Legal Officer |
| Ms. Jennifer Champoux | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | glue-20260507.htm |
| 2026-05-07 | 10-Q | glue-20260331.htm |
| 2026-04-29 | ARS | ars_4.29.26.pdf |
| 2026-03-17 | S-8 | glue-20260317.htm |
| 2026-02-11 | S-3ASR | d72009ds3asr.htm |
| 2026-02-10 | 8-K | glue-20260209.htm |
| 2026-01-09 | 8-K | d36015d8k.htm |
| 2026-01-07 | 8-K | glue-20260107.htm |
| 2025-12-16 | 8-K | glue-20251216.htm |
| 2025-11-06 | 10-Q | glue-20250930.htm |